Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
3,628
archived clinical trials in
Schizophrenia

CSP #572 - Genetics of Functional Disability in Schizophrenia and Bipolar Illness
CSP #572 - Genetics of Functional Disability in Schizophrenia and Bipolar Illness
Status: Enrolling
Updated:  6/9/2014
Philadelphia VA Medical Center, Philadelphia, PA
2371
mi
from 98109
Philadelphia, PA
CSP #572 - Genetics of Functional Disability in Schizophrenia and Bipolar Illness
CSP #572 - Genetics of Functional Disability in Schizophrenia and Bipolar Illness
Status: Enrolling
Updated: 6/9/2014
Philadelphia VA Medical Center, Philadelphia, PA
2371
mi
from 98109
Philadelphia, PA
Click here to add this to my saved trials
CSP #572 - Genetics of Functional Disability in Schizophrenia and Bipolar Illness
CSP #572 - Genetics of Functional Disability in Schizophrenia and Bipolar Illness
Status: Enrolling
Updated:  6/9/2014
VA Pittsburgh Healthcare System University Drive Division, Pittsburgh, PA
2131
mi
from 98109
Pittsburgh, PA
CSP #572 - Genetics of Functional Disability in Schizophrenia and Bipolar Illness
CSP #572 - Genetics of Functional Disability in Schizophrenia and Bipolar Illness
Status: Enrolling
Updated: 6/9/2014
VA Pittsburgh Healthcare System University Drive Division, Pittsburgh, PA
2131
mi
from 98109
Pittsburgh, PA
Click here to add this to my saved trials
CSP #572 - Genetics of Functional Disability in Schizophrenia and Bipolar Illness
CSP #572 - Genetics of Functional Disability in Schizophrenia and Bipolar Illness
Status: Enrolling
Updated:  6/9/2014
Ralph H. Johnson VA Medical Center, Charleston, SC
2423
mi
from 98109
Charleston, SC
CSP #572 - Genetics of Functional Disability in Schizophrenia and Bipolar Illness
CSP #572 - Genetics of Functional Disability in Schizophrenia and Bipolar Illness
Status: Enrolling
Updated: 6/9/2014
Ralph H. Johnson VA Medical Center, Charleston, SC
2423
mi
from 98109
Charleston, SC
Click here to add this to my saved trials
CSP #572 - Genetics of Functional Disability in Schizophrenia and Bipolar Illness
CSP #572 - Genetics of Functional Disability in Schizophrenia and Bipolar Illness
Status: Enrolling
Updated:  6/9/2014
Michael E. DeBakey VA Medical Center, Houston, TX
1892
mi
from 98109
Houston, TX
CSP #572 - Genetics of Functional Disability in Schizophrenia and Bipolar Illness
CSP #572 - Genetics of Functional Disability in Schizophrenia and Bipolar Illness
Status: Enrolling
Updated: 6/9/2014
Michael E. DeBakey VA Medical Center, Houston, TX
1892
mi
from 98109
Houston, TX
Click here to add this to my saved trials
CSP #572 - Genetics of Functional Disability in Schizophrenia and Bipolar Illness
CSP #572 - Genetics of Functional Disability in Schizophrenia and Bipolar Illness
Status: Enrolling
Updated:  6/9/2014
Central Texas Veterans Health Care System Waco VA Medical Center, Waco, TX
1726
mi
from 98109
Waco, TX
CSP #572 - Genetics of Functional Disability in Schizophrenia and Bipolar Illness
CSP #572 - Genetics of Functional Disability in Schizophrenia and Bipolar Illness
Status: Enrolling
Updated: 6/9/2014
Central Texas Veterans Health Care System Waco VA Medical Center, Waco, TX
1726
mi
from 98109
Waco, TX
Click here to add this to my saved trials
CSP #572 - Genetics of Functional Disability in Schizophrenia and Bipolar Illness
CSP #572 - Genetics of Functional Disability in Schizophrenia and Bipolar Illness
Status: Enrolling
Updated:  6/9/2014
VA Puget Sound Health Care System American Lake Division, Tacoma, WA
26
mi
from 98109
Tacoma, WA
CSP #572 - Genetics of Functional Disability in Schizophrenia and Bipolar Illness
CSP #572 - Genetics of Functional Disability in Schizophrenia and Bipolar Illness
Status: Enrolling
Updated: 6/9/2014
VA Puget Sound Health Care System American Lake Division, Tacoma, WA
26
mi
from 98109
Tacoma, WA
Click here to add this to my saved trials
An Randomized Open-Label PK Study of LY03004 Compared to Risperdal® Consta® in Stable Patients With Schizophrenia or Schizoaffective Disorder
A Randomized, Open-Label Pharmacokinetic Study of LY03004 Compared to Risperdal® Consta® Following a Single Intramuscular Injection at 25 mg in Stable Patients With Schizophrenia and/or Schizoaffective Disorder
Status: Enrolling
Updated:  7/8/2014
Neuropsychiatric Research Center of Orange County
991
mi
from 98109
Orange County, CA
An Randomized Open-Label PK Study of LY03004 Compared to Risperdal® Consta® in Stable Patients With Schizophrenia or Schizoaffective Disorder
A Randomized, Open-Label Pharmacokinetic Study of LY03004 Compared to Risperdal® Consta® Following a Single Intramuscular Injection at 25 mg in Stable Patients With Schizophrenia and/or Schizoaffective Disorder
Status: Enrolling
Updated: 7/8/2014
Neuropsychiatric Research Center of Orange County
991
mi
from 98109
Orange County, CA
Click here to add this to my saved trials
An Randomized Open-Label PK Study of LY03004 Compared to Risperdal® Consta® in Stable Patients With Schizophrenia or Schizoaffective Disorder
A Randomized, Open-Label Pharmacokinetic Study of LY03004 Compared to Risperdal® Consta® Following a Single Intramuscular Injection at 25 mg in Stable Patients With Schizophrenia and/or Schizoaffective Disorder
Status: Enrolling
Updated:  7/8/2014
Community Clinical Research
1770
mi
from 98109
Austin, TX
An Randomized Open-Label PK Study of LY03004 Compared to Risperdal® Consta® in Stable Patients With Schizophrenia or Schizoaffective Disorder
A Randomized, Open-Label Pharmacokinetic Study of LY03004 Compared to Risperdal® Consta® Following a Single Intramuscular Injection at 25 mg in Stable Patients With Schizophrenia and/or Schizoaffective Disorder
Status: Enrolling
Updated: 7/8/2014
Community Clinical Research
1770
mi
from 98109
Austin, TX
Click here to add this to my saved trials
Safety and Tolerability of Multiple Doses of ITI-214 in Healthy Adults and in Adults With Stable Schizophrenia
A Phase 1, Randomized, Placebo- Controlled, Double-Blind Safety, Tolerability, Pharmacokinetic, and Exploratory Pharmacodynamic Study in Healthy Subjects and Subjects With Stable Schizophrenia After Multiple Doses of ITI-214
Status: Enrolling
Updated:  7/28/2014
Clinical Research Facility
955
mi
from 98109
Glendale, CA
Safety and Tolerability of Multiple Doses of ITI-214 in Healthy Adults and in Adults With Stable Schizophrenia
A Phase 1, Randomized, Placebo- Controlled, Double-Blind Safety, Tolerability, Pharmacokinetic, and Exploratory Pharmacodynamic Study in Healthy Subjects and Subjects With Stable Schizophrenia After Multiple Doses of ITI-214
Status: Enrolling
Updated: 7/28/2014
Clinical Research Facility
955
mi
from 98109
Glendale, CA
Click here to add this to my saved trials
Safety and Tolerability of Multiple Doses of ITI-214 in Healthy Adults and in Adults With Stable Schizophrenia
A Phase 1, Randomized, Placebo- Controlled, Double-Blind Safety, Tolerability, Pharmacokinetic, and Exploratory Pharmacodynamic Study in Healthy Subjects and Subjects With Stable Schizophrenia After Multiple Doses of ITI-214
Status: Enrolling
Updated:  7/28/2014
Clinical Research Facility
2400
mi
from 98109
New York, NY
Safety and Tolerability of Multiple Doses of ITI-214 in Healthy Adults and in Adults With Stable Schizophrenia
A Phase 1, Randomized, Placebo- Controlled, Double-Blind Safety, Tolerability, Pharmacokinetic, and Exploratory Pharmacodynamic Study in Healthy Subjects and Subjects With Stable Schizophrenia After Multiple Doses of ITI-214
Status: Enrolling
Updated: 7/28/2014
Clinical Research Facility
2400
mi
from 98109
New York, NY
Click here to add this to my saved trials
An Outpatient Study Of The Efficacy, Safety, And Tolerability Of PF-02545920 In The Adjunctive Treatment Of Sub-Optimally Controlled Symptoms of Schizophrenia
A 12-Week, Randomized, Phase 2, Double-Blind, Parallel-Group Study Of Two Dose Levels Of PF-02545920 Compared To Placebo In The Adjunctive Treatment Of Outpatients With Sub-Optimally Controlled Symptoms Of Schizophrenia
Status: Enrolling
Updated:  8/11/2014
Pfizer Investigational Site
2081
mi
from 98109
Birmingham, AL
An Outpatient Study Of The Efficacy, Safety, And Tolerability Of PF-02545920 In The Adjunctive Treatment Of Sub-Optimally Controlled Symptoms of Schizophrenia
A 12-Week, Randomized, Phase 2, Double-Blind, Parallel-Group Study Of Two Dose Levels Of PF-02545920 Compared To Placebo In The Adjunctive Treatment Of Outpatients With Sub-Optimally Controlled Symptoms Of Schizophrenia
Status: Enrolling
Updated: 8/11/2014
Pfizer Investigational Site
2081
mi
from 98109
Birmingham, AL
Click here to add this to my saved trials
An Outpatient Study Of The Efficacy, Safety, And Tolerability Of PF-02545920 In The Adjunctive Treatment Of Sub-Optimally Controlled Symptoms of Schizophrenia
A 12-Week, Randomized, Phase 2, Double-Blind, Parallel-Group Study Of Two Dose Levels Of PF-02545920 Compared To Placebo In The Adjunctive Treatment Of Outpatients With Sub-Optimally Controlled Symptoms Of Schizophrenia
Status: Enrolling
Updated:  8/11/2014
Pfizer Investigational Site
1779
mi
from 98109
Little Rock, AR
An Outpatient Study Of The Efficacy, Safety, And Tolerability Of PF-02545920 In The Adjunctive Treatment Of Sub-Optimally Controlled Symptoms of Schizophrenia
A 12-Week, Randomized, Phase 2, Double-Blind, Parallel-Group Study Of Two Dose Levels Of PF-02545920 Compared To Placebo In The Adjunctive Treatment Of Outpatients With Sub-Optimally Controlled Symptoms Of Schizophrenia
Status: Enrolling
Updated: 8/11/2014
Pfizer Investigational Site
1779
mi
from 98109
Little Rock, AR
Click here to add this to my saved trials
An Outpatient Study Of The Efficacy, Safety, And Tolerability Of PF-02545920 In The Adjunctive Treatment Of Sub-Optimally Controlled Symptoms of Schizophrenia
A 12-Week, Randomized, Phase 2, Double-Blind, Parallel-Group Study Of Two Dose Levels Of PF-02545920 Compared To Placebo In The Adjunctive Treatment Of Outpatients With Sub-Optimally Controlled Symptoms Of Schizophrenia
Status: Enrolling
Updated:  8/11/2014
Pfizer Investigational Site
977
mi
from 98109
Cerritos, CA
An Outpatient Study Of The Efficacy, Safety, And Tolerability Of PF-02545920 In The Adjunctive Treatment Of Sub-Optimally Controlled Symptoms of Schizophrenia
A 12-Week, Randomized, Phase 2, Double-Blind, Parallel-Group Study Of Two Dose Levels Of PF-02545920 Compared To Placebo In The Adjunctive Treatment Of Outpatients With Sub-Optimally Controlled Symptoms Of Schizophrenia
Status: Enrolling
Updated: 8/11/2014
Pfizer Investigational Site
977
mi
from 98109
Cerritos, CA
Click here to add this to my saved trials
An Outpatient Study Of The Efficacy, Safety, And Tolerability Of PF-02545920 In The Adjunctive Treatment Of Sub-Optimally Controlled Symptoms of Schizophrenia
A 12-Week, Randomized, Phase 2, Double-Blind, Parallel-Group Study Of Two Dose Levels Of PF-02545920 Compared To Placebo In The Adjunctive Treatment Of Outpatients With Sub-Optimally Controlled Symptoms Of Schizophrenia
Status: Enrolling
Updated:  8/11/2014
Pfizer Investigational Site
964
mi
from 98109
Culver City, CA
An Outpatient Study Of The Efficacy, Safety, And Tolerability Of PF-02545920 In The Adjunctive Treatment Of Sub-Optimally Controlled Symptoms of Schizophrenia
A 12-Week, Randomized, Phase 2, Double-Blind, Parallel-Group Study Of Two Dose Levels Of PF-02545920 Compared To Placebo In The Adjunctive Treatment Of Outpatients With Sub-Optimally Controlled Symptoms Of Schizophrenia
Status: Enrolling
Updated: 8/11/2014
Pfizer Investigational Site
964
mi
from 98109
Culver City, CA
Click here to add this to my saved trials
An Outpatient Study Of The Efficacy, Safety, And Tolerability Of PF-02545920 In The Adjunctive Treatment Of Sub-Optimally Controlled Symptoms of Schizophrenia
A 12-Week, Randomized, Phase 2, Double-Blind, Parallel-Group Study Of Two Dose Levels Of PF-02545920 Compared To Placebo In The Adjunctive Treatment Of Outpatients With Sub-Optimally Controlled Symptoms Of Schizophrenia
Status: Enrolling
Updated:  8/11/2014
Pfizer Investigational Site
1042
mi
from 98109
Escondido, CA
An Outpatient Study Of The Efficacy, Safety, And Tolerability Of PF-02545920 In The Adjunctive Treatment Of Sub-Optimally Controlled Symptoms of Schizophrenia
A 12-Week, Randomized, Phase 2, Double-Blind, Parallel-Group Study Of Two Dose Levels Of PF-02545920 Compared To Placebo In The Adjunctive Treatment Of Outpatients With Sub-Optimally Controlled Symptoms Of Schizophrenia
Status: Enrolling
Updated: 8/11/2014
Pfizer Investigational Site
1042
mi
from 98109
Escondido, CA
Click here to add this to my saved trials
An Outpatient Study Of The Efficacy, Safety, And Tolerability Of PF-02545920 In The Adjunctive Treatment Of Sub-Optimally Controlled Symptoms of Schizophrenia
A 12-Week, Randomized, Phase 2, Double-Blind, Parallel-Group Study Of Two Dose Levels Of PF-02545920 Compared To Placebo In The Adjunctive Treatment Of Outpatients With Sub-Optimally Controlled Symptoms Of Schizophrenia
Status: Enrolling
Updated:  8/11/2014
Pfizer Investigational Site
982
mi
from 98109
Garden Grove, CA
An Outpatient Study Of The Efficacy, Safety, And Tolerability Of PF-02545920 In The Adjunctive Treatment Of Sub-Optimally Controlled Symptoms of Schizophrenia
A 12-Week, Randomized, Phase 2, Double-Blind, Parallel-Group Study Of Two Dose Levels Of PF-02545920 Compared To Placebo In The Adjunctive Treatment Of Outpatients With Sub-Optimally Controlled Symptoms Of Schizophrenia
Status: Enrolling
Updated: 8/11/2014
Pfizer Investigational Site
982
mi
from 98109
Garden Grove, CA
Click here to add this to my saved trials
An Outpatient Study Of The Efficacy, Safety, And Tolerability Of PF-02545920 In The Adjunctive Treatment Of Sub-Optimally Controlled Symptoms of Schizophrenia
A 12-Week, Randomized, Phase 2, Double-Blind, Parallel-Group Study Of Two Dose Levels Of PF-02545920 Compared To Placebo In The Adjunctive Treatment Of Outpatients With Sub-Optimally Controlled Symptoms Of Schizophrenia
Status: Enrolling
Updated:  8/11/2014
Pfizer Investigational Site
677
mi
from 98109
Oakland, CA
An Outpatient Study Of The Efficacy, Safety, And Tolerability Of PF-02545920 In The Adjunctive Treatment Of Sub-Optimally Controlled Symptoms of Schizophrenia
A 12-Week, Randomized, Phase 2, Double-Blind, Parallel-Group Study Of Two Dose Levels Of PF-02545920 Compared To Placebo In The Adjunctive Treatment Of Outpatients With Sub-Optimally Controlled Symptoms Of Schizophrenia
Status: Enrolling
Updated: 8/11/2014
Pfizer Investigational Site
677
mi
from 98109
Oakland, CA
Click here to add this to my saved trials
An Outpatient Study Of The Efficacy, Safety, And Tolerability Of PF-02545920 In The Adjunctive Treatment Of Sub-Optimally Controlled Symptoms of Schizophrenia
A 12-Week, Randomized, Phase 2, Double-Blind, Parallel-Group Study Of Two Dose Levels Of PF-02545920 Compared To Placebo In The Adjunctive Treatment Of Outpatients With Sub-Optimally Controlled Symptoms Of Schizophrenia
Status: Enrolling
Updated:  8/11/2014
Pfizer Investigational Site
1031
mi
from 98109
Oceanside, CA
An Outpatient Study Of The Efficacy, Safety, And Tolerability Of PF-02545920 In The Adjunctive Treatment Of Sub-Optimally Controlled Symptoms of Schizophrenia
A 12-Week, Randomized, Phase 2, Double-Blind, Parallel-Group Study Of Two Dose Levels Of PF-02545920 Compared To Placebo In The Adjunctive Treatment Of Outpatients With Sub-Optimally Controlled Symptoms Of Schizophrenia
Status: Enrolling
Updated: 8/11/2014
Pfizer Investigational Site
1031
mi
from 98109
Oceanside, CA
Click here to add this to my saved trials
An Outpatient Study Of The Efficacy, Safety, And Tolerability Of PF-02545920 In The Adjunctive Treatment Of Sub-Optimally Controlled Symptoms of Schizophrenia
A 12-Week, Randomized, Phase 2, Double-Blind, Parallel-Group Study Of Two Dose Levels Of PF-02545920 Compared To Placebo In The Adjunctive Treatment Of Outpatients With Sub-Optimally Controlled Symptoms Of Schizophrenia
Status: Enrolling
Updated:  8/11/2014
Pfizer Investigational Site
984
mi
from 98109
Orange, CA
An Outpatient Study Of The Efficacy, Safety, And Tolerability Of PF-02545920 In The Adjunctive Treatment Of Sub-Optimally Controlled Symptoms of Schizophrenia
A 12-Week, Randomized, Phase 2, Double-Blind, Parallel-Group Study Of Two Dose Levels Of PF-02545920 Compared To Placebo In The Adjunctive Treatment Of Outpatients With Sub-Optimally Controlled Symptoms Of Schizophrenia
Status: Enrolling
Updated: 8/11/2014
Pfizer Investigational Site
984
mi
from 98109
Orange, CA
Click here to add this to my saved trials
An Outpatient Study Of The Efficacy, Safety, And Tolerability Of PF-02545920 In The Adjunctive Treatment Of Sub-Optimally Controlled Symptoms of Schizophrenia
A 12-Week, Randomized, Phase 2, Double-Blind, Parallel-Group Study Of Two Dose Levels Of PF-02545920 Compared To Placebo In The Adjunctive Treatment Of Outpatients With Sub-Optimally Controlled Symptoms Of Schizophrenia
Status: Enrolling
Updated:  8/11/2014
Pfizer Investigational Site
980
mi
from 98109
Riverside, CA
An Outpatient Study Of The Efficacy, Safety, And Tolerability Of PF-02545920 In The Adjunctive Treatment Of Sub-Optimally Controlled Symptoms of Schizophrenia
A 12-Week, Randomized, Phase 2, Double-Blind, Parallel-Group Study Of Two Dose Levels Of PF-02545920 Compared To Placebo In The Adjunctive Treatment Of Outpatients With Sub-Optimally Controlled Symptoms Of Schizophrenia
Status: Enrolling
Updated: 8/11/2014
Pfizer Investigational Site
980
mi
from 98109
Riverside, CA
Click here to add this to my saved trials
An Outpatient Study Of The Efficacy, Safety, And Tolerability Of PF-02545920 In The Adjunctive Treatment Of Sub-Optimally Controlled Symptoms of Schizophrenia
A 12-Week, Randomized, Phase 2, Double-Blind, Parallel-Group Study Of Two Dose Levels Of PF-02545920 Compared To Placebo In The Adjunctive Treatment Of Outpatients With Sub-Optimally Controlled Symptoms Of Schizophrenia
Status: Enrolling
Updated:  8/11/2014
Pfizer Investigational Site
1059
mi
from 98109
San Diego, CA
An Outpatient Study Of The Efficacy, Safety, And Tolerability Of PF-02545920 In The Adjunctive Treatment Of Sub-Optimally Controlled Symptoms of Schizophrenia
A 12-Week, Randomized, Phase 2, Double-Blind, Parallel-Group Study Of Two Dose Levels Of PF-02545920 Compared To Placebo In The Adjunctive Treatment Of Outpatients With Sub-Optimally Controlled Symptoms Of Schizophrenia
Status: Enrolling
Updated: 8/11/2014
Pfizer Investigational Site
1059
mi
from 98109
San Diego, CA
Click here to add this to my saved trials
An Outpatient Study Of The Efficacy, Safety, And Tolerability Of PF-02545920 In The Adjunctive Treatment Of Sub-Optimally Controlled Symptoms of Schizophrenia
A 12-Week, Randomized, Phase 2, Double-Blind, Parallel-Group Study Of Two Dose Levels Of PF-02545920 Compared To Placebo In The Adjunctive Treatment Of Outpatients With Sub-Optimally Controlled Symptoms Of Schizophrenia
Status: Enrolling
Updated:  8/11/2014
Pfizer Investigational Site
1059
mi
from 98109
San Diego, CA
An Outpatient Study Of The Efficacy, Safety, And Tolerability Of PF-02545920 In The Adjunctive Treatment Of Sub-Optimally Controlled Symptoms of Schizophrenia
A 12-Week, Randomized, Phase 2, Double-Blind, Parallel-Group Study Of Two Dose Levels Of PF-02545920 Compared To Placebo In The Adjunctive Treatment Of Outpatients With Sub-Optimally Controlled Symptoms Of Schizophrenia
Status: Enrolling
Updated: 8/11/2014
Pfizer Investigational Site
1059
mi
from 98109
San Diego, CA
Click here to add this to my saved trials
An Outpatient Study Of The Efficacy, Safety, And Tolerability Of PF-02545920 In The Adjunctive Treatment Of Sub-Optimally Controlled Symptoms of Schizophrenia
A 12-Week, Randomized, Phase 2, Double-Blind, Parallel-Group Study Of Two Dose Levels Of PF-02545920 Compared To Placebo In The Adjunctive Treatment Of Outpatients With Sub-Optimally Controlled Symptoms Of Schizophrenia
Status: Enrolling
Updated:  8/11/2014
Pfizer Investigational Site
976
mi
from 98109
Torrance, CA
An Outpatient Study Of The Efficacy, Safety, And Tolerability Of PF-02545920 In The Adjunctive Treatment Of Sub-Optimally Controlled Symptoms of Schizophrenia
A 12-Week, Randomized, Phase 2, Double-Blind, Parallel-Group Study Of Two Dose Levels Of PF-02545920 Compared To Placebo In The Adjunctive Treatment Of Outpatients With Sub-Optimally Controlled Symptoms Of Schizophrenia
Status: Enrolling
Updated: 8/11/2014
Pfizer Investigational Site
976
mi
from 98109
Torrance, CA
Click here to add this to my saved trials
An Outpatient Study Of The Efficacy, Safety, And Tolerability Of PF-02545920 In The Adjunctive Treatment Of Sub-Optimally Controlled Symptoms of Schizophrenia
A 12-Week, Randomized, Phase 2, Double-Blind, Parallel-Group Study Of Two Dose Levels Of PF-02545920 Compared To Placebo In The Adjunctive Treatment Of Outpatients With Sub-Optimally Controlled Symptoms Of Schizophrenia
Status: Enrolling
Updated:  8/11/2014
Pfizer Investigational Site
2429
mi
from 98109
Hartford, CT
An Outpatient Study Of The Efficacy, Safety, And Tolerability Of PF-02545920 In The Adjunctive Treatment Of Sub-Optimally Controlled Symptoms of Schizophrenia
A 12-Week, Randomized, Phase 2, Double-Blind, Parallel-Group Study Of Two Dose Levels Of PF-02545920 Compared To Placebo In The Adjunctive Treatment Of Outpatients With Sub-Optimally Controlled Symptoms Of Schizophrenia
Status: Enrolling
Updated: 8/11/2014
Pfizer Investigational Site
2429
mi
from 98109
Hartford, CT
Click here to add this to my saved trials
An Outpatient Study Of The Efficacy, Safety, And Tolerability Of PF-02545920 In The Adjunctive Treatment Of Sub-Optimally Controlled Symptoms of Schizophrenia
A 12-Week, Randomized, Phase 2, Double-Blind, Parallel-Group Study Of Two Dose Levels Of PF-02545920 Compared To Placebo In The Adjunctive Treatment Of Outpatients With Sub-Optimally Controlled Symptoms Of Schizophrenia
Status: Enrolling
Updated:  8/11/2014
Pfizer Investigational Site
2432
mi
from 98109
New Haven, CT
An Outpatient Study Of The Efficacy, Safety, And Tolerability Of PF-02545920 In The Adjunctive Treatment Of Sub-Optimally Controlled Symptoms of Schizophrenia
A 12-Week, Randomized, Phase 2, Double-Blind, Parallel-Group Study Of Two Dose Levels Of PF-02545920 Compared To Placebo In The Adjunctive Treatment Of Outpatients With Sub-Optimally Controlled Symptoms Of Schizophrenia
Status: Enrolling
Updated: 8/11/2014
Pfizer Investigational Site
2432
mi
from 98109
New Haven, CT
Click here to add this to my saved trials
An Outpatient Study Of The Efficacy, Safety, And Tolerability Of PF-02545920 In The Adjunctive Treatment Of Sub-Optimally Controlled Symptoms of Schizophrenia
A 12-Week, Randomized, Phase 2, Double-Blind, Parallel-Group Study Of Two Dose Levels Of PF-02545920 Compared To Placebo In The Adjunctive Treatment Of Outpatients With Sub-Optimally Controlled Symptoms Of Schizophrenia
Status: Enrolling
Updated:  8/11/2014
Pfizer Investigational Site
2322
mi
from 98109
Washington,
An Outpatient Study Of The Efficacy, Safety, And Tolerability Of PF-02545920 In The Adjunctive Treatment Of Sub-Optimally Controlled Symptoms of Schizophrenia
A 12-Week, Randomized, Phase 2, Double-Blind, Parallel-Group Study Of Two Dose Levels Of PF-02545920 Compared To Placebo In The Adjunctive Treatment Of Outpatients With Sub-Optimally Controlled Symptoms Of Schizophrenia
Status: Enrolling
Updated: 8/11/2014
Pfizer Investigational Site
2322
mi
from 98109
Washington,
Click here to add this to my saved trials
An Outpatient Study Of The Efficacy, Safety, And Tolerability Of PF-02545920 In The Adjunctive Treatment Of Sub-Optimally Controlled Symptoms of Schizophrenia
A 12-Week, Randomized, Phase 2, Double-Blind, Parallel-Group Study Of Two Dose Levels Of PF-02545920 Compared To Placebo In The Adjunctive Treatment Of Outpatients With Sub-Optimally Controlled Symptoms Of Schizophrenia
Status: Enrolling
Updated:  8/11/2014
Pfizer Investigational Site
2543
mi
from 98109
Bradenton, FL
An Outpatient Study Of The Efficacy, Safety, And Tolerability Of PF-02545920 In The Adjunctive Treatment Of Sub-Optimally Controlled Symptoms of Schizophrenia
A 12-Week, Randomized, Phase 2, Double-Blind, Parallel-Group Study Of Two Dose Levels Of PF-02545920 Compared To Placebo In The Adjunctive Treatment Of Outpatients With Sub-Optimally Controlled Symptoms Of Schizophrenia
Status: Enrolling
Updated: 8/11/2014
Pfizer Investigational Site
2543
mi
from 98109
Bradenton, FL
Click here to add this to my saved trials
An Outpatient Study Of The Efficacy, Safety, And Tolerability Of PF-02545920 In The Adjunctive Treatment Of Sub-Optimally Controlled Symptoms of Schizophrenia
A 12-Week, Randomized, Phase 2, Double-Blind, Parallel-Group Study Of Two Dose Levels Of PF-02545920 Compared To Placebo In The Adjunctive Treatment Of Outpatients With Sub-Optimally Controlled Symptoms Of Schizophrenia
Status: Enrolling
Updated:  8/11/2014
Pfizer Investigational Site
2713
mi
from 98109
Lauderhill, FL
An Outpatient Study Of The Efficacy, Safety, And Tolerability Of PF-02545920 In The Adjunctive Treatment Of Sub-Optimally Controlled Symptoms of Schizophrenia
A 12-Week, Randomized, Phase 2, Double-Blind, Parallel-Group Study Of Two Dose Levels Of PF-02545920 Compared To Placebo In The Adjunctive Treatment Of Outpatients With Sub-Optimally Controlled Symptoms Of Schizophrenia
Status: Enrolling
Updated: 8/11/2014
Pfizer Investigational Site
2713
mi
from 98109
Lauderhill, FL
Click here to add this to my saved trials
An Outpatient Study Of The Efficacy, Safety, And Tolerability Of PF-02545920 In The Adjunctive Treatment Of Sub-Optimally Controlled Symptoms of Schizophrenia
A 12-Week, Randomized, Phase 2, Double-Blind, Parallel-Group Study Of Two Dose Levels Of PF-02545920 Compared To Placebo In The Adjunctive Treatment Of Outpatients With Sub-Optimally Controlled Symptoms Of Schizophrenia
Status: Enrolling
Updated:  8/11/2014
Pfizer Investigational Site
2539
mi
from 98109
Sanford, FL
An Outpatient Study Of The Efficacy, Safety, And Tolerability Of PF-02545920 In The Adjunctive Treatment Of Sub-Optimally Controlled Symptoms of Schizophrenia
A 12-Week, Randomized, Phase 2, Double-Blind, Parallel-Group Study Of Two Dose Levels Of PF-02545920 Compared To Placebo In The Adjunctive Treatment Of Outpatients With Sub-Optimally Controlled Symptoms Of Schizophrenia
Status: Enrolling
Updated: 8/11/2014
Pfizer Investigational Site
2539
mi
from 98109
Sanford, FL
Click here to add this to my saved trials
An Outpatient Study Of The Efficacy, Safety, And Tolerability Of PF-02545920 In The Adjunctive Treatment Of Sub-Optimally Controlled Symptoms of Schizophrenia
A 12-Week, Randomized, Phase 2, Double-Blind, Parallel-Group Study Of Two Dose Levels Of PF-02545920 Compared To Placebo In The Adjunctive Treatment Of Outpatients With Sub-Optimally Controlled Symptoms Of Schizophrenia
Status: Enrolling
Updated:  8/11/2014
Pfizer Investigational Site
2177
mi
from 98109
Atlanta, GA
An Outpatient Study Of The Efficacy, Safety, And Tolerability Of PF-02545920 In The Adjunctive Treatment Of Sub-Optimally Controlled Symptoms of Schizophrenia
A 12-Week, Randomized, Phase 2, Double-Blind, Parallel-Group Study Of Two Dose Levels Of PF-02545920 Compared To Placebo In The Adjunctive Treatment Of Outpatients With Sub-Optimally Controlled Symptoms Of Schizophrenia
Status: Enrolling
Updated: 8/11/2014
Pfizer Investigational Site
2177
mi
from 98109
Atlanta, GA
Click here to add this to my saved trials
An Outpatient Study Of The Efficacy, Safety, And Tolerability Of PF-02545920 In The Adjunctive Treatment Of Sub-Optimally Controlled Symptoms of Schizophrenia
A 12-Week, Randomized, Phase 2, Double-Blind, Parallel-Group Study Of Two Dose Levels Of PF-02545920 Compared To Placebo In The Adjunctive Treatment Of Outpatients With Sub-Optimally Controlled Symptoms Of Schizophrenia
Status: Enrolling
Updated:  8/11/2014
Pfizer Investigational Site
1705
mi
from 98109
Hoffman Estates, IL
An Outpatient Study Of The Efficacy, Safety, And Tolerability Of PF-02545920 In The Adjunctive Treatment Of Sub-Optimally Controlled Symptoms of Schizophrenia
A 12-Week, Randomized, Phase 2, Double-Blind, Parallel-Group Study Of Two Dose Levels Of PF-02545920 Compared To Placebo In The Adjunctive Treatment Of Outpatients With Sub-Optimally Controlled Symptoms Of Schizophrenia
Status: Enrolling
Updated: 8/11/2014
Pfizer Investigational Site
1705
mi
from 98109
Hoffman Estates, IL
Click here to add this to my saved trials
An Outpatient Study Of The Efficacy, Safety, And Tolerability Of PF-02545920 In The Adjunctive Treatment Of Sub-Optimally Controlled Symptoms of Schizophrenia
A 12-Week, Randomized, Phase 2, Double-Blind, Parallel-Group Study Of Two Dose Levels Of PF-02545920 Compared To Placebo In The Adjunctive Treatment Of Outpatients With Sub-Optimally Controlled Symptoms Of Schizophrenia
Status: Enrolling
Updated:  8/11/2014
Pfizer Investigational Site
1706
mi
from 98109
Schaumburg, IL
An Outpatient Study Of The Efficacy, Safety, And Tolerability Of PF-02545920 In The Adjunctive Treatment Of Sub-Optimally Controlled Symptoms of Schizophrenia
A 12-Week, Randomized, Phase 2, Double-Blind, Parallel-Group Study Of Two Dose Levels Of PF-02545920 Compared To Placebo In The Adjunctive Treatment Of Outpatients With Sub-Optimally Controlled Symptoms Of Schizophrenia
Status: Enrolling
Updated: 8/11/2014
Pfizer Investigational Site
1706
mi
from 98109
Schaumburg, IL
Click here to add this to my saved trials
An Outpatient Study Of The Efficacy, Safety, And Tolerability Of PF-02545920 In The Adjunctive Treatment Of Sub-Optimally Controlled Symptoms of Schizophrenia
A 12-Week, Randomized, Phase 2, Double-Blind, Parallel-Group Study Of Two Dose Levels Of PF-02545920 Compared To Placebo In The Adjunctive Treatment Of Outpatients With Sub-Optimally Controlled Symptoms Of Schizophrenia
Status: Enrolling
Updated:  8/11/2014
Pfizer Investigational Site
1954
mi
from 98109
Lake Charles, LA
An Outpatient Study Of The Efficacy, Safety, And Tolerability Of PF-02545920 In The Adjunctive Treatment Of Sub-Optimally Controlled Symptoms of Schizophrenia
A 12-Week, Randomized, Phase 2, Double-Blind, Parallel-Group Study Of Two Dose Levels Of PF-02545920 Compared To Placebo In The Adjunctive Treatment Of Outpatients With Sub-Optimally Controlled Symptoms Of Schizophrenia
Status: Enrolling
Updated: 8/11/2014
Pfizer Investigational Site
1954
mi
from 98109
Lake Charles, LA
Click here to add this to my saved trials
An Outpatient Study Of The Efficacy, Safety, And Tolerability Of PF-02545920 In The Adjunctive Treatment Of Sub-Optimally Controlled Symptoms of Schizophrenia
A 12-Week, Randomized, Phase 2, Double-Blind, Parallel-Group Study Of Two Dose Levels Of PF-02545920 Compared To Placebo In The Adjunctive Treatment Of Outpatients With Sub-Optimally Controlled Symptoms Of Schizophrenia
Status: Enrolling
Updated:  8/11/2014
Pfizer Investigational Site
1843
mi
from 98109
Shreveport, LA
An Outpatient Study Of The Efficacy, Safety, And Tolerability Of PF-02545920 In The Adjunctive Treatment Of Sub-Optimally Controlled Symptoms of Schizophrenia
A 12-Week, Randomized, Phase 2, Double-Blind, Parallel-Group Study Of Two Dose Levels Of PF-02545920 Compared To Placebo In The Adjunctive Treatment Of Outpatients With Sub-Optimally Controlled Symptoms Of Schizophrenia
Status: Enrolling
Updated: 8/11/2014
Pfizer Investigational Site
1843
mi
from 98109
Shreveport, LA
Click here to add this to my saved trials
An Outpatient Study Of The Efficacy, Safety, And Tolerability Of PF-02545920 In The Adjunctive Treatment Of Sub-Optimally Controlled Symptoms of Schizophrenia
A 12-Week, Randomized, Phase 2, Double-Blind, Parallel-Group Study Of Two Dose Levels Of PF-02545920 Compared To Placebo In The Adjunctive Treatment Of Outpatients With Sub-Optimally Controlled Symptoms Of Schizophrenia
Status: Enrolling
Updated:  8/11/2014
Pfizer Investigational Site
2317
mi
from 98109
Rockville, MD
An Outpatient Study Of The Efficacy, Safety, And Tolerability Of PF-02545920 In The Adjunctive Treatment Of Sub-Optimally Controlled Symptoms of Schizophrenia
A 12-Week, Randomized, Phase 2, Double-Blind, Parallel-Group Study Of Two Dose Levels Of PF-02545920 Compared To Placebo In The Adjunctive Treatment Of Outpatients With Sub-Optimally Controlled Symptoms Of Schizophrenia
Status: Enrolling
Updated: 8/11/2014
Pfizer Investigational Site
2317
mi
from 98109
Rockville, MD
Click here to add this to my saved trials
An Outpatient Study Of The Efficacy, Safety, And Tolerability Of PF-02545920 In The Adjunctive Treatment Of Sub-Optimally Controlled Symptoms of Schizophrenia
A 12-Week, Randomized, Phase 2, Double-Blind, Parallel-Group Study Of Two Dose Levels Of PF-02545920 Compared To Placebo In The Adjunctive Treatment Of Outpatients With Sub-Optimally Controlled Symptoms Of Schizophrenia
Status: Enrolling
Updated:  8/11/2014
Pfizer Investigational Site
1692
mi
from 98109
O'Fallon, MO
An Outpatient Study Of The Efficacy, Safety, And Tolerability Of PF-02545920 In The Adjunctive Treatment Of Sub-Optimally Controlled Symptoms of Schizophrenia
A 12-Week, Randomized, Phase 2, Double-Blind, Parallel-Group Study Of Two Dose Levels Of PF-02545920 Compared To Placebo In The Adjunctive Treatment Of Outpatients With Sub-Optimally Controlled Symptoms Of Schizophrenia
Status: Enrolling
Updated: 8/11/2014
Pfizer Investigational Site
1692
mi
from 98109
O'Fallon, MO
Click here to add this to my saved trials
An Outpatient Study Of The Efficacy, Safety, And Tolerability Of PF-02545920 In The Adjunctive Treatment Of Sub-Optimally Controlled Symptoms of Schizophrenia
A 12-Week, Randomized, Phase 2, Double-Blind, Parallel-Group Study Of Two Dose Levels Of PF-02545920 Compared To Placebo In The Adjunctive Treatment Of Outpatients With Sub-Optimally Controlled Symptoms Of Schizophrenia
Status: Enrolling
Updated:  8/11/2014
Pfizer Investigational Site
1718
mi
from 98109
St. Louis, MO
An Outpatient Study Of The Efficacy, Safety, And Tolerability Of PF-02545920 In The Adjunctive Treatment Of Sub-Optimally Controlled Symptoms of Schizophrenia
A 12-Week, Randomized, Phase 2, Double-Blind, Parallel-Group Study Of Two Dose Levels Of PF-02545920 Compared To Placebo In The Adjunctive Treatment Of Outpatients With Sub-Optimally Controlled Symptoms Of Schizophrenia
Status: Enrolling
Updated: 8/11/2014
Pfizer Investigational Site
1718
mi
from 98109
St. Louis, MO
Click here to add this to my saved trials
An Outpatient Study Of The Efficacy, Safety, And Tolerability Of PF-02545920 In The Adjunctive Treatment Of Sub-Optimally Controlled Symptoms of Schizophrenia
A 12-Week, Randomized, Phase 2, Double-Blind, Parallel-Group Study Of Two Dose Levels Of PF-02545920 Compared To Placebo In The Adjunctive Treatment Of Outpatients With Sub-Optimally Controlled Symptoms Of Schizophrenia
Status: Enrolling
Updated:  8/11/2014
Pfizer Investigational Site
868
mi
from 98109
Las Vegas, NV
An Outpatient Study Of The Efficacy, Safety, And Tolerability Of PF-02545920 In The Adjunctive Treatment Of Sub-Optimally Controlled Symptoms of Schizophrenia
A 12-Week, Randomized, Phase 2, Double-Blind, Parallel-Group Study Of Two Dose Levels Of PF-02545920 Compared To Placebo In The Adjunctive Treatment Of Outpatients With Sub-Optimally Controlled Symptoms Of Schizophrenia
Status: Enrolling
Updated: 8/11/2014
Pfizer Investigational Site
868
mi
from 98109
Las Vegas, NV
Click here to add this to my saved trials
An Outpatient Study Of The Efficacy, Safety, And Tolerability Of PF-02545920 In The Adjunctive Treatment Of Sub-Optimally Controlled Symptoms of Schizophrenia
A 12-Week, Randomized, Phase 2, Double-Blind, Parallel-Group Study Of Two Dose Levels Of PF-02545920 Compared To Placebo In The Adjunctive Treatment Of Outpatients With Sub-Optimally Controlled Symptoms Of Schizophrenia
Status: Enrolling
Updated:  8/11/2014
Pfizer Investigational Site
2412
mi
from 98109
Jamaica, NY
An Outpatient Study Of The Efficacy, Safety, And Tolerability Of PF-02545920 In The Adjunctive Treatment Of Sub-Optimally Controlled Symptoms of Schizophrenia
A 12-Week, Randomized, Phase 2, Double-Blind, Parallel-Group Study Of Two Dose Levels Of PF-02545920 Compared To Placebo In The Adjunctive Treatment Of Outpatients With Sub-Optimally Controlled Symptoms Of Schizophrenia
Status: Enrolling
Updated: 8/11/2014
Pfizer Investigational Site
2412
mi
from 98109
Jamaica, NY
Click here to add this to my saved trials
An Outpatient Study Of The Efficacy, Safety, And Tolerability Of PF-02545920 In The Adjunctive Treatment Of Sub-Optimally Controlled Symptoms of Schizophrenia
A 12-Week, Randomized, Phase 2, Double-Blind, Parallel-Group Study Of Two Dose Levels Of PF-02545920 Compared To Placebo In The Adjunctive Treatment Of Outpatients With Sub-Optimally Controlled Symptoms Of Schizophrenia
Status: Enrolling
Updated:  8/11/2014
Pfizer Investigational Site
2402
mi
from 98109
New York, NY
An Outpatient Study Of The Efficacy, Safety, And Tolerability Of PF-02545920 In The Adjunctive Treatment Of Sub-Optimally Controlled Symptoms of Schizophrenia
A 12-Week, Randomized, Phase 2, Double-Blind, Parallel-Group Study Of Two Dose Levels Of PF-02545920 Compared To Placebo In The Adjunctive Treatment Of Outpatients With Sub-Optimally Controlled Symptoms Of Schizophrenia
Status: Enrolling
Updated: 8/11/2014
Pfizer Investigational Site
2402
mi
from 98109
New York, NY
Click here to add this to my saved trials
An Outpatient Study Of The Efficacy, Safety, And Tolerability Of PF-02545920 In The Adjunctive Treatment Of Sub-Optimally Controlled Symptoms of Schizophrenia
A 12-Week, Randomized, Phase 2, Double-Blind, Parallel-Group Study Of Two Dose Levels Of PF-02545920 Compared To Placebo In The Adjunctive Treatment Of Outpatients With Sub-Optimally Controlled Symptoms Of Schizophrenia
Status: Enrolling
Updated:  8/11/2014
Pfizer Investigational Site
1956
mi
from 98109
Dayton, OH
An Outpatient Study Of The Efficacy, Safety, And Tolerability Of PF-02545920 In The Adjunctive Treatment Of Sub-Optimally Controlled Symptoms of Schizophrenia
A 12-Week, Randomized, Phase 2, Double-Blind, Parallel-Group Study Of Two Dose Levels Of PF-02545920 Compared To Placebo In The Adjunctive Treatment Of Outpatients With Sub-Optimally Controlled Symptoms Of Schizophrenia
Status: Enrolling
Updated: 8/11/2014
Pfizer Investigational Site
1956
mi
from 98109
Dayton, OH
Click here to add this to my saved trials
An Outpatient Study Of The Efficacy, Safety, And Tolerability Of PF-02545920 In The Adjunctive Treatment Of Sub-Optimally Controlled Symptoms of Schizophrenia
A 12-Week, Randomized, Phase 2, Double-Blind, Parallel-Group Study Of Two Dose Levels Of PF-02545920 Compared To Placebo In The Adjunctive Treatment Of Outpatients With Sub-Optimally Controlled Symptoms Of Schizophrenia
Status: Enrolling
Updated:  8/11/2014
Pfizer Investigational Site
1519
mi
from 98109
Oklahoma City, OK
An Outpatient Study Of The Efficacy, Safety, And Tolerability Of PF-02545920 In The Adjunctive Treatment Of Sub-Optimally Controlled Symptoms of Schizophrenia
A 12-Week, Randomized, Phase 2, Double-Blind, Parallel-Group Study Of Two Dose Levels Of PF-02545920 Compared To Placebo In The Adjunctive Treatment Of Outpatients With Sub-Optimally Controlled Symptoms Of Schizophrenia
Status: Enrolling
Updated: 8/11/2014
Pfizer Investigational Site
1519
mi
from 98109
Oklahoma City, OK
Click here to add this to my saved trials
An Outpatient Study Of The Efficacy, Safety, And Tolerability Of PF-02545920 In The Adjunctive Treatment Of Sub-Optimally Controlled Symptoms of Schizophrenia
A 12-Week, Randomized, Phase 2, Double-Blind, Parallel-Group Study Of Two Dose Levels Of PF-02545920 Compared To Placebo In The Adjunctive Treatment Of Outpatients With Sub-Optimally Controlled Symptoms Of Schizophrenia
Status: Enrolling
Updated:  8/11/2014
Pfizer Investigational Site
1863
mi
from 98109
Memphis, TN
An Outpatient Study Of The Efficacy, Safety, And Tolerability Of PF-02545920 In The Adjunctive Treatment Of Sub-Optimally Controlled Symptoms of Schizophrenia
A 12-Week, Randomized, Phase 2, Double-Blind, Parallel-Group Study Of Two Dose Levels Of PF-02545920 Compared To Placebo In The Adjunctive Treatment Of Outpatients With Sub-Optimally Controlled Symptoms Of Schizophrenia
Status: Enrolling
Updated: 8/11/2014
Pfizer Investigational Site
1863
mi
from 98109
Memphis, TN
Click here to add this to my saved trials
An Outpatient Study Of The Efficacy, Safety, And Tolerability Of PF-02545920 In The Adjunctive Treatment Of Sub-Optimally Controlled Symptoms of Schizophrenia
A 12-Week, Randomized, Phase 2, Double-Blind, Parallel-Group Study Of Two Dose Levels Of PF-02545920 Compared To Placebo In The Adjunctive Treatment Of Outpatients With Sub-Optimally Controlled Symptoms Of Schizophrenia
Status: Enrolling
Updated:  8/11/2014
Pfizer Investigational Site
1766
mi
from 98109
Austin, TX
An Outpatient Study Of The Efficacy, Safety, And Tolerability Of PF-02545920 In The Adjunctive Treatment Of Sub-Optimally Controlled Symptoms of Schizophrenia
A 12-Week, Randomized, Phase 2, Double-Blind, Parallel-Group Study Of Two Dose Levels Of PF-02545920 Compared To Placebo In The Adjunctive Treatment Of Outpatients With Sub-Optimally Controlled Symptoms Of Schizophrenia
Status: Enrolling
Updated: 8/11/2014
Pfizer Investigational Site
1766
mi
from 98109
Austin, TX
Click here to add this to my saved trials
An Outpatient Study Of The Efficacy, Safety, And Tolerability Of PF-02545920 In The Adjunctive Treatment Of Sub-Optimally Controlled Symptoms of Schizophrenia
A 12-Week, Randomized, Phase 2, Double-Blind, Parallel-Group Study Of Two Dose Levels Of PF-02545920 Compared To Placebo In The Adjunctive Treatment Of Outpatients With Sub-Optimally Controlled Symptoms Of Schizophrenia
Status: Enrolling
Updated:  8/11/2014
Pfizer Investigational Site
1766
mi
from 98109
Austin, TX
An Outpatient Study Of The Efficacy, Safety, And Tolerability Of PF-02545920 In The Adjunctive Treatment Of Sub-Optimally Controlled Symptoms of Schizophrenia
A 12-Week, Randomized, Phase 2, Double-Blind, Parallel-Group Study Of Two Dose Levels Of PF-02545920 Compared To Placebo In The Adjunctive Treatment Of Outpatients With Sub-Optimally Controlled Symptoms Of Schizophrenia
Status: Enrolling
Updated: 8/11/2014
Pfizer Investigational Site
1766
mi
from 98109
Austin, TX
Click here to add this to my saved trials
An Outpatient Study Of The Efficacy, Safety, And Tolerability Of PF-02545920 In The Adjunctive Treatment Of Sub-Optimally Controlled Symptoms of Schizophrenia
A 12-Week, Randomized, Phase 2, Double-Blind, Parallel-Group Study Of Two Dose Levels Of PF-02545920 Compared To Placebo In The Adjunctive Treatment Of Outpatients With Sub-Optimally Controlled Symptoms Of Schizophrenia
Status: Enrolling
Updated:  8/11/2014
Pfizer Investigational Site
1680
mi
from 98109
Dallas, TX
An Outpatient Study Of The Efficacy, Safety, And Tolerability Of PF-02545920 In The Adjunctive Treatment Of Sub-Optimally Controlled Symptoms of Schizophrenia
A 12-Week, Randomized, Phase 2, Double-Blind, Parallel-Group Study Of Two Dose Levels Of PF-02545920 Compared To Placebo In The Adjunctive Treatment Of Outpatients With Sub-Optimally Controlled Symptoms Of Schizophrenia
Status: Enrolling
Updated: 8/11/2014
Pfizer Investigational Site
1680
mi
from 98109
Dallas, TX
Click here to add this to my saved trials
An Outpatient Study Of The Efficacy, Safety, And Tolerability Of PF-02545920 In The Adjunctive Treatment Of Sub-Optimally Controlled Symptoms of Schizophrenia
A 12-Week, Randomized, Phase 2, Double-Blind, Parallel-Group Study Of Two Dose Levels Of PF-02545920 Compared To Placebo In The Adjunctive Treatment Of Outpatients With Sub-Optimally Controlled Symptoms Of Schizophrenia
Status: Enrolling
Updated:  8/11/2014
Pfizer Investigational Site
1680
mi
from 98109
Dallas, TX
An Outpatient Study Of The Efficacy, Safety, And Tolerability Of PF-02545920 In The Adjunctive Treatment Of Sub-Optimally Controlled Symptoms of Schizophrenia
A 12-Week, Randomized, Phase 2, Double-Blind, Parallel-Group Study Of Two Dose Levels Of PF-02545920 Compared To Placebo In The Adjunctive Treatment Of Outpatients With Sub-Optimally Controlled Symptoms Of Schizophrenia
Status: Enrolling
Updated: 8/11/2014
Pfizer Investigational Site
1680
mi
from 98109
Dallas, TX
Click here to add this to my saved trials
An Outpatient Study Of The Efficacy, Safety, And Tolerability Of PF-02545920 In The Adjunctive Treatment Of Sub-Optimally Controlled Symptoms of Schizophrenia
A 12-Week, Randomized, Phase 2, Double-Blind, Parallel-Group Study Of Two Dose Levels Of PF-02545920 Compared To Placebo In The Adjunctive Treatment Of Outpatients With Sub-Optimally Controlled Symptoms Of Schizophrenia
Status: Enrolling
Updated:  8/11/2014
Pfizer Investigational Site
1687
mi
from 98109
DeSoto, TX
An Outpatient Study Of The Efficacy, Safety, And Tolerability Of PF-02545920 In The Adjunctive Treatment Of Sub-Optimally Controlled Symptoms of Schizophrenia
A 12-Week, Randomized, Phase 2, Double-Blind, Parallel-Group Study Of Two Dose Levels Of PF-02545920 Compared To Placebo In The Adjunctive Treatment Of Outpatients With Sub-Optimally Controlled Symptoms Of Schizophrenia
Status: Enrolling
Updated: 8/11/2014
Pfizer Investigational Site
1687
mi
from 98109
DeSoto, TX
Click here to add this to my saved trials
An Outpatient Study Of The Efficacy, Safety, And Tolerability Of PF-02545920 In The Adjunctive Treatment Of Sub-Optimally Controlled Symptoms of Schizophrenia
A 12-Week, Randomized, Phase 2, Double-Blind, Parallel-Group Study Of Two Dose Levels Of PF-02545920 Compared To Placebo In The Adjunctive Treatment Of Outpatients With Sub-Optimally Controlled Symptoms Of Schizophrenia
Status: Enrolling
Updated:  8/11/2014
Pfizer Investigational Site
1892
mi
from 98109
Houston, TX
An Outpatient Study Of The Efficacy, Safety, And Tolerability Of PF-02545920 In The Adjunctive Treatment Of Sub-Optimally Controlled Symptoms of Schizophrenia
A 12-Week, Randomized, Phase 2, Double-Blind, Parallel-Group Study Of Two Dose Levels Of PF-02545920 Compared To Placebo In The Adjunctive Treatment Of Outpatients With Sub-Optimally Controlled Symptoms Of Schizophrenia
Status: Enrolling
Updated: 8/11/2014
Pfizer Investigational Site
1892
mi
from 98109
Houston, TX
Click here to add this to my saved trials
An Outpatient Study Of The Efficacy, Safety, And Tolerability Of PF-02545920 In The Adjunctive Treatment Of Sub-Optimally Controlled Symptoms of Schizophrenia
A 12-Week, Randomized, Phase 2, Double-Blind, Parallel-Group Study Of Two Dose Levels Of PF-02545920 Compared To Placebo In The Adjunctive Treatment Of Outpatients With Sub-Optimally Controlled Symptoms Of Schizophrenia
Status: Enrolling
Updated:  8/11/2014
Pfizer Investigational Site
700
mi
from 98109
Salt Lake City, UT
An Outpatient Study Of The Efficacy, Safety, And Tolerability Of PF-02545920 In The Adjunctive Treatment Of Sub-Optimally Controlled Symptoms of Schizophrenia
A 12-Week, Randomized, Phase 2, Double-Blind, Parallel-Group Study Of Two Dose Levels Of PF-02545920 Compared To Placebo In The Adjunctive Treatment Of Outpatients With Sub-Optimally Controlled Symptoms Of Schizophrenia
Status: Enrolling
Updated: 8/11/2014
Pfizer Investigational Site
700
mi
from 98109
Salt Lake City, UT
Click here to add this to my saved trials